Glenmark Pharma Targets 23% Core Margins by FY27, Driven by Global Expansion and New Products
Loading more articles...
Glenmark Pharma Targets 23% Core Margins by FY27, Strong Growth Across Markets
C
CNBC TV18•13-02-2026, 12:52
Glenmark Pharma Targets 23% Core Margins by FY27, Strong Growth Across Markets
•Glenmark Pharma projects core business margins to reach 23% by FY27, an increase of 100-150 basis points next year.
•India remains a key growth driver, with 10-15% growth expected, supported by new product launches like Tevimbra and Brukinsa.
•US revenues are set to rebound with new product launches and regulatory advancements at the Monroe facility.
•Europe will contribute with Winlevi launched in the UK and planned expansion into larger EU markets; Ryaltris and emerging markets show steady progress.
•The company is on track to become debt-free by March and is already in a significantly positive net cash position.
